Target intelligence / Profile preview

Immunoglobulin G1 antibody Fc region (IgG1 Fc)

Target
IgG1 Fc
Molecular classification
Antibody fragment, Immunoglobulin domain, Glycoprotein, Other
01

Overview

The Immunoglobulin G1 antibody Fc region (IgG1 Fc) is the constant tail portion of the IgG1 antibody. It is formed by the C-terminal domains of the heavy chains (CH2 and CH3) and is linked by disulfide bonds and non-covalent interactions. The Fc region is distinct from the Fab (antigen-binding) arms and is highly conserved within a species. Its central role is to mediate various immune effector functions by engaging specific cell surface Fc gamma receptors (FcγRs) and complement proteins, leading to activities such as ADCC, CDC, phagocytosis, and immune modulation. The IgG1 Fc also binds to the neonatal Fc receptor (FcRn), governing antibody half-life and recycling. Therapeutic monoclonal antibodies are commonly formatted as human IgG1 because its Fc region robustly recruits immune effector mechanisms and is well characterized. Engineering of the IgG1 Fc region can tune effector functions, stability, and pharmacokinetics, but may also introduce safety or immunogenicity risks.

Other names
IgG1 Fc fragmentIgG1 crystallizable fragmentIgG1 fragment crystallizable regionFc region of IgG1
02

Mechanism of action

Fcγ receptor engagement mediating effector cell activation (e.g., NK cell-mediated ADCC); Complement binding leading to complement-dependent cytotoxicity (CDC); Neonatal Fc receptor (FcRn) binding regulating antibody half-life and transport; Immune complex formation and opsonization

03

Biological functions

Immune responseAntibody-dependent cellular cytotoxicity (ADCC)Complement activationPhagocytosisImmune regulationOther
04

Disease associations

CancerInflammationAutoimmune diseaseInfectionOther
05

Safety considerations

Excessive immune activation leading to cytokine release syndromeOff-target cytotoxicity (e.g., cell lysis, inflammation)Immunogenicity of engineered Fc or altered glycosylationCross-reactivity with endogenous IgG or Fcγ receptorsReduced efficacy due to FcγR polymorphisms or altered glycosylation
06

Interacting drugs

Rituximab

5 more in the full profile.

07

Biomarkers

Fcγ receptor polymorphisms (for patient response stratification)Serum IgG1 levels (in certain immune diseases)Glycosylation status of Fc (for predicting effector function)

Beyond the preview

Go deeper on Immunoglobulin G1 antibody Fc region (IgG1 Fc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin G1 antibody Fc region (IgG1 Fc).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call